Oxidativer Stress & Kardiovaskuläre Erkrankungen

Produktname

sSEMA4D

soluble Semaphorin 4D

Kat-Nr.BI-20405
Bereich0 – 2,000 pmol/l
Sensitivität31 pmol/l (STD2 62.5 pmol/l)
Inkubationszeit4.5 hours
Probenmenge10 μl
Probentyp

Plasma

Probenvorbereitung

Centrifuge freshly collected blood as soon as possible
Store centrifuged samples at -20°C for longer storage.
Samples are stable up to 4 freeze and thaw cycles.
Hemolyzed or lipemic samples may cause erroneous results.

Referenzwerte

Median EDTA plasma (n=44): 245 pmol/l
Median citrate plasma (n=43): 192 pmol/l
Median heparin plasma (n=28): 201 pmol/l

Spezies

Human

Tests96
MethodeELISA
Anwendung

Intended use:

Semaphorin 4D (SEMA4D or CD100) is a member of a family of transmembrane and secreted proteins that regulates key cellular functions and is involved in cell-cell communication (1-3). Most of the effects of SEMA4D is mediated by plexins (4, 5). SEMA4D participates in numerous physiological processes such as axon guidance, immune regulation, angiogenesis, tumor progression, and bone metabolism (6-9). Cleavage of SEMA4D near the cell membrane through matrix metalloproteinases leads to the biologically active soluble SEMA4D with a molecular weight of 120 kD consisting of 713 amino acids (3, 5, 10). SEMA4D has emerged to a novel therapeutic target in cancer and in bone diseases (11, 12). Semaphorin 4D is widely studied for ist role in neural connectivity, vascularization, cell migration, the immune response, tumor progression, and bone remodeling. This sSEMA4D ELISA utilizes two monoclonal anti-human Semaphorin 4D antibodies, both recognizing conformational epitopes on Semaphorin 4D. The epitopes have been mapped by overlapping cyclic peptides and shown to involve amino acids AA30-AA34 and amino acids AA238-AA241, respectively (for further information on antibody characterization please visit our website www.bmgrp.com: see Validation Data)

Intended applications:

Osteology
Neurology
Immunology
Oncology

Produktinformation

Zurück zur Übersicht